A gene expression signature classifying telomerase and ALT immortalization reveals an hTERT regulatory network and suggests a mesenchymal stem cell origin for ALT

Oncogene

Volumn 28, Issue 43, 2009, Pages 3765-3774

  Lafferty Whyte, K ^a   Cairney, C J ^a   Will, M B ^a   Serakinci, N ^b   Daidone, M G ^c   Zaffaroni, N ^c   Bilsland, A ^a   Keith, W N ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

ALT; C Myc; Mesenchymal; Microarray; Signalling; Telomerase

Indexed keywords

TELOMERASE REVERSE TRANSCRIPTASE;

ARTICLE; CELL IMMORTALIZATION; CHROMATIN ASSEMBLY AND DISASSEMBLY; CONTROLLED STUDY; FEMALE; GENE CLUSTER; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE INTERACTION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; LIPOSARCOMA; MESENCHYMAL STEM CELL; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; SIGNAL TRANSDUCTION; TELOMERE;

CELL LINE, TUMOR; GENE EXPRESSION PROFILING; HUMANS; LIPOSARCOMA; MESENCHYMAL STEM CELLS; PROTO-ONCOGENE PROTEINS C-MYC; TELOMERASE; TELOMERE;

EID: 70350692066     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2009.238     Document Type: Article

References (32)

1. Atkinson SP, Hoare SF, Glasspool RM, Keith WN. (2005). Lack of telomerase gene expression in alternative lengthening of telomere cells is associated with chromatin remodeling of the hTR and hTERT gene promoters. Cancer Res 65: 7585-7590.
2. Bernardo ME, Zaffaroni N, Novara F, Cometa AM, Avanzini MA, Moretta A et al. (2007). Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. Cancer Res 67: 9142-9149.
3. Bryan TM, Englezou A, Dalla-Pozza L, Dunham MA, Reddel RR. (1997). Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat Med 3: 1271-1274.
4. Cairney CJ, Hoare SF, Daidone MG, Zaffaroni N, Keith WN. (2008). High level of telomerase RNA gene expression is associated with chromatin modification, the ALT phenotype and poor prognosis in liposarcoma. Br J Cancer 98: 1467-1474.
5. Cairney CJ, Keith WN. (2008). Telomerase redefined: integrated regulation of hTR and hTERT for telomere maintenance and telomerase activity. Biochimie 90: 13-23.
6. Chen YJ, Hakin-Smith V, Teo M, Xinarianos GE, Jellinek DA, Carroll T et al. (2006). Association of mutant TP53 with alternative lengthening of telomeres and favorable prognosis in glioma. Cancer Res 66: 6473-6476.
7. Costa A, Daidone MG, Daprai L, Villa R, Cantu S, Pilotti S et al. (2006). Telomere maintenance mechanisms in liposarcomas: association with histologic subtypes and disease progression. Cancer Res 66: 8918-8924.
8. Gibbs CP, Kukekov VG, Reith JD, Tchigrinova O, Suslov ON, Scott EW et al. (2005). Stem-like cells in bone sarcomas: implications for tumorigenesis. Neoplasia 7: 967-976.
9. Hakin-Smith V, Jellinek DA, Levy D, Carroll T, Teo M, Timperley WR et al. (2003). Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme. Lancet 361: 836-838.
10. Hao H, Nancai Y, Lei F, Xiong W, Wen S, Guofu H et al. (2008). siRNA directed against c-Myc inhibits proliferation and down-regulates human telomerase reverse transcriptase in human colon cancer Colo 320 cells. J Exp Clin Cancer Res 27: 27.
11. Henson JD, Hannay JA, McCarthy SW, Royds JA, Yeager TR, Robinson RA et al. (2005). A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas. Clin Cancer Res 11: 217-225.
12. Henson JD, Neumann AA, Yeager TR, Reddel RR. (2002). Alternative lengthening of telomeres in mammalian cells. Oncogene 21: 598-610.
13. Huang PR, Tsai ST, Hsieh KH, Wang TC. (2008). Heterogeneous nuclear ribonucleoprotein A3 binds single-stranded telomeric DNA and inhibits telomerase extension in vitro. Biochim Biophys Acta 1783: 193-202.
14. Jiang WQ, Zhong ZH, Henson JD, Reddel RR. (2007). Identification of candidate alternative lengthening of telomeres genes by methionine restriction and RNA interference. Oncogene 26: 4635-4647.
15. Johnson JE, Varkonyi RJ, Schwalm J, Cragle R, Klein-Szanto A, Patchefsky A et al. (2005). Multiple mechanisms of telomere maintenance exist in liposarcomas. Clin Cancer Res 11: 5347-5355.
16. Matushansky I, Hernando E, Socci ND, Mills JE, Matos TA, Edgar MA et al. (2007). Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathway. J Clin Invest 117: 3248-3257.
17. Mehle C, Piatyszek MA, Ljungberg B, Shay JW, Roos G. (1996). Telomerase activity in human renal cell carcinoma. Oncogene 13: 161-166.
18. Miura M, Miura Y, Padilla-Nash HM, Molinolo AA, Fu B, Patel V et al. (2006). Accumulated chromosomal instability in murine bone marrow mesenchymal stem cells leads to malignant transformation. Stem Cells 24: 1095-1103.
19. Riggi N, Suva ML, Suva D, Cironi L, Provero P, Tercier S et al. (2008). EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells. Cancer Res 68: 2176-2185.
20. Rubio D, Garcia-Castro J, Martin MC, de la Fuente R, Cigudosa JC, Lloyd AC et al. (2005). Spontaneous human adult stem cell transformation. Cancer Res 65: 3035-3039.
21. Serakinci N, Guldberg P, Burns JS, Abdallah B, Schrodder H, Jensen T et al. (2004). Adult human mesenchymal stem cell as a target for neoplastic transformation. Oncogene 23: 5095-5098.
22. Serakinci N, Hoare SF, Kassem M, Atkinson SP, Keith WN. (2006). Telomerase promoter reprogramming and interaction with general transcription factors in the human mesenchymal stem cell. Regen Med 1: 125-131.
23. Tirode F, Laud-Duval K, Prieur A, Delorme B, Charbord P, Delattre O. (2007). Mesenchymal stem cell features of Ewing tumors. Cancer Cell 11: 421-429.
24. Ulaner GA, Hoffman AR, Otero J, Huang HY, Zhao Z, Mazumdar M et al. (2004). Divergent patterns of telomere maintenance mechanisms among human sarcomas: sharply contrasting prevalence of the alternative lengthening of telomeres mechanism in Ewing's sarcomas and osteosarcomas. Genes Chromosomes Cancer 41: 155-162.
25. Ulaner GA, Huang HY, Otero J, Zhao Z, Ben-Porat L, Satagopan JM et al. (2003). Absence of a telomere maintenance mechanism as a favorable prognostic factor in patients with osteosarcoma. Cancer Res 63: 1759-1763.
26. Wang Y, Huso DL, Harrington J, Kellner J, Jeong DK, Turney J et al. (2005). Outgrowth of a transformed cell population derived from normal human BM mesenchymal stem cell culture. Cytotherapy 7: 509-519.
27. Wu C, Wei Q, Utomo V, Nadesan P, Whetstone H, Kandel R et al. (2007). Side population cells isolated from mesenchymal neoplasms have tumor initiating potential. Cancer Res 67: 8216-8222.
28. Yeager TR, Neumann AA, Englezou A, Huschtscha LI, Noble JR, Reddel RR. (1999). Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body. Cancer Res 59: 4175-4179.
29. Zhao YM, Li JY, Lan JP, Lai XY, Luo Y, Sun J et al. (2008). Cell cycle dependent telomere regulation by telomerase in human bone marrow mesenchymal stem cells. Biochem Biophys Res Commun 369: 1114-1119.
30. Zhong ZH, Jiang WQ, Cesare AJ, Neumann AA, Wadhwa R, Reddel RR. (2007). Disruption of telomere maintenance by depletion of the MRE11/RAD50/NBS1 complex in cells that use alternative lengthening of telomeres. J Biol Chem 282: 29314-29322.
31. Zhou YF, Bosch-Marce M, Okuyama H, Krishnamachary B, Kimura H, Zhang L et al. (2006). Spontaneous transformation of cultured mouse bone marrow-derived stromal cells. Cancer Res 66: 10849-10854.
32. Zimmermann S, Voss M, Kaiser S, Kapp U, Waller CF, Martens UM. (2003). Lack of telomerase activity in human mesenchymal stem cells. Leukemia 17: 1146-1149.